Carisma Therapeutics Stock Operating Margin
| CARM Stock | 0.85 0.01 1.19% |
Carisma Therapeutics fundamentals help investors to digest information that contributes to Carisma Therapeutics' financial success or failures. It also enables traders to predict the movement of Carisma Stock. The fundamental analysis module provides a way to measure Carisma Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carisma Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (5.95) | (6.24) |
Carisma | Operating Margin |
Carisma Therapeutics Company Operating Margin Analysis
Carisma Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Carisma Therapeutics Operating Margin | (3.88) % |
Most of Carisma Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carisma Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Carisma Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Carisma Therapeutics is extremely important. It helps to project a fair market value of Carisma Stock properly, considering its historical fundamentals such as Operating Margin. Since Carisma Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Carisma Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Carisma Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Carisma Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Carisma Therapeutics has an Operating Margin of -3.883%. This is 88.93% lower than that of the Biotechnology sector and 96.54% lower than that of the Health Care industry. The operating margin for all United States stocks is 29.53% lower than that of the firm.
Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Carisma Fundamentals
| Return On Equity | -3.63 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (3.88) % | ||||
| Current Valuation | 12.1 M | ||||
| Shares Outstanding | 41.75 M | ||||
| Shares Owned By Insiders | 28.53 % | ||||
| Shares Owned By Institutions | 31.51 % | ||||
| Number Of Shares Shorted | 558.58 K | ||||
| Price To Book | 114.10 X | ||||
| Price To Sales | 1.76 X | ||||
| Revenue | 14.92 M | ||||
| EBITDA | (85.89 M) | ||||
| Net Income | (86.88 M) | ||||
| Total Debt | 3.12 M | ||||
| Book Value Per Share | (0.27) X | ||||
| Cash Flow From Operations | (81.18 M) | ||||
| Short Ratio | 3.11 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Target Price | 9.8 | ||||
| Number Of Employees | 107 | ||||
| Market Capitalization | 35.65 M | ||||
| Total Asset | 89.55 M | ||||
| Retained Earnings | (245.1 M) | ||||
| Working Capital | 64.56 M | ||||
| Net Asset | 89.55 M |
About Carisma Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carisma Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carisma Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carisma Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Carisma Therapeutics Piotroski F Score and Carisma Therapeutics Altman Z Score analysis. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.